B. Metzler seel. Sohn & Co
BMRN icon

B. Metzler seel. Sohn & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History

B. Metzler seel. Sohn & Co’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,889
Closed -$265K – 727
2025
Q3 		$265K Hold
4,889
– – ﹤0.01% 710
2025
Q2 		$269K Hold
4,889
– – ﹤0.01% 706
2025
Q1 		$346K Hold
4,889
– – ﹤0.01% 674
2024
Q4 		$321K Hold
4,889
– – ﹤0.01% 698
2024
Q3 		$344K Sell
4,889
-2,546
-34% -$213K ﹤0.01% 695
2024
Q2 		$612K Buy
7,435
+219
+3% +$18.2K 0.01% 612
2024
Q1 		$630K Sell
7,216
-2,300
-24% -$206K 0.01% 588
2023
Q4 		$918K Hold
9,516
– – 0.01% 517
2023
Q3 		$842K Buy
9,516
+1,430
+18% +$127K 0.01% 500
2023
Q2 		$701K Sell
8,086
-58,400
-88% -$5.5M 0.01% 538
2023
Q1 		$6.47M Hold
66,486
– – 0.1% 131
2022
Q4 		$6.88M Sell
66,486
-1,977
-3% -$186K 0.12% 120
2022
Q3 		$5.8M Buy
68,463
+58,464
+585% +$5.21M 0.11% 137
2022
Q2 		$828K Buy
9,999
+4,300
+75% +$342K 0.01% 481
2022
Q1 		$439K Buy
5,699
+362
+7% +$30.3K 0.01% 624
2021
Q4 		$475K Sell
5,337
-6,225
-54% -$514K 0.01% 565
2021
Q3 		$894K Buy
11,562
+2,581
+29% +$204K 0.01% 460
2021
Q2 		$749K Buy
8,981
+694
+8% +$55K 0.01% 487
2021
Q1 		$626K Sell
8,287
-17,100
-67% -$1.4M 0.01% 510
2020
Q4 		$2.21M Buy
+25,387
New +$2.01M 0.04% 252

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

B. Metzler seel. Sohn & Co's BMRN Position: Q4 2025 in Review

B. Metzler seel. Sohn & Co sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 4,889 shares — an estimated $265K sold.

B. Metzler seel. Sohn & Co first reported a position in BMRN in Q4 2020 and held it in 20 quarters. The position peaked at $6.88M in Q4 2022. 541 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

  • B. Metzler seel. Sohn & Co reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • B. Metzler seel. Sohn & Co sold 4,889 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $265K.
  • B. Metzler seel. Sohn & Co first reported a position in BioMarin Pharmaceuticals in Q4 2020 and held it in 20 quarters.
  • B. Metzler seel. Sohn & Co's BioMarin Pharmaceuticals position peaked at $6.88M in Q4 2022.
  • 541 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q4 2025, filed 28 Jan 2026.